



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

BL-1020 mesylate

Cat. No.:	HY-111136
CAS No.:	916898-61-8
Molecular Formula:	C ₂₆ H ₃₇ ClN ₄ O ₅ S ₂
Molecular Weight:	585.18
Target:	GABA Receptor; 5-HT Receptor; Dopamine Receptor; Histamine Receptor
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling; GPCR/G Protein; Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	BL-1020 mesylate is the mesylate salt form of BL-1020. BL-1020 mesylate is an antipsychotic agent. BL-1020 mesylate is inhibitor for dopamine receptor and serotonin receptor (5-HT receptor), with K _i of 0.066, 0.062 and 0.21 nM, for D _{2L} , D _{2S} and 5-HT _{2A} receptors, respectively. BL-1020 mesylate is agonist for GABA _A receptor with K _i of 3.74 μM, and enhances the GABA release. BL-1020 mesylate exhibits high affinity with histamine receptor (K _i is 0.47 nM). BL-1020 mesylate reduces Amphetamine-induced hyperactivity, with lower catalepsy and sedation. BL-1020 mesylate is blood-brain barrier penetrate [1].		
IC₅₀ & Target	D_{2L} Receptor 0.066 nM (K _i)	Histamine Receptor 0.47 nM (K _i)	5-HT_{2A} Receptor 3.74 μM (K _i)

REFERENCES

[1]. Geffen Y, et al., BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. *Eur Neuropsychopharmacol.* 2009 Jan;19(1):1-13.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA